Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing

Chemistry and Biology

Volumn 22, Issue 1, 2015, Pages 107-116

  Neggers, Jasper E ^a   Vercruysse, Thomas ^a   Jacquemyn, Maarten ^a   Vanstreels, Els ^a   Baloglu, Erkan ^b   Shacham, Sharon ^b   Crochiere, Marsha ^b   Landesman, Yosef ^b   Daelemans, Dirk ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Karyopharm Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; EXPORTIN 1; SELINEXOR; ANTINEOPLASTIC AGENT; CELL RECEPTOR; EXPORTIN 1 PROTEIN; HYDRAZINE DERIVATIVE; KARYOPHERIN; KPT-330; PROTEIN BINDING; TRIAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL MUTANT; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG TARGETING; GENE; GENE MUTATION; GENOME; HOMOZYGOSITY; HUMAN; HUMAN CELL; MAMMAL CELL; PRIORITY JOURNAL; XPO1 GENE; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; HOMOLOGOUS RECOMBINATION; JURKAT CELL LINE; KINETICS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE;

MAMMALIA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL CYCLE CHECKPOINTS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; DRUG DELIVERY SYSTEMS; HOMOLOGOUS RECOMBINATION; HUMANS; HYDRAZINES; JURKAT CELLS; KARYOPHERINS; KINETICS; MUTATION; PROTEIN BINDING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRIAZOLES;

EID: 84921442369     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2014.11.015     Document Type: Article

References (51)

1. A. Aloisi, S. Di Gregorio, F. Stagno, P. Guglielmo, F. Mannino, M.P. Sormani, P. Bruzzi, C. Gambacorti-Passerini, G. Saglio, and S. Venuta BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B Blood 107 2006 1591 1598
2. Chen, C., Gutierrez, M., de Nully Brown, P., Gabrail, N., Baz, R., Flinn, I., Trudel, S., Siegel, D., Mau-Sorensen, M., Reece, D., et al. (2014). Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed/Refractory Multiple Myeloma (MM) Or Waldenstrom's Macroglobulinemia (WM). https://ash.confex.com/ash/2013/webprogram/Paper61462.html.
3. Y. Cheng, M.P. Holloway, K. Nguyen, D. McCauley, Y. Landesman, M.G. Kauffman, S. Shacham, and R.A. Altura XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer Mol. Cancer Ther. 13 2014 675 686
4. S.W. Cho, S. Kim, J.M. Kim, and J.S. Kim Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease Nat. Biotechnol. 31 2013 230 232
5. S.V. Costes, D. Daelemans, E.H. Cho, Z. Dobbin, G. Pavlakis, and S. Lockett Automatic and quantitative measurement of protein-protein colocalization in live cells Biophys. J. 86 2004 3993 4003
6. D. Daelemans, E. Afonina, J. Nilsson, G. Werner, J. Kjems, E. De Clercq, G.N. Pavlakis, and A.M. Vandamme A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export Proc. Natl. Acad. Sci. USA 99 2002 14440 14445
7. D. Daelemans, S.V. Costes, S. Lockett, and G.N. Pavlakis Kinetic and molecular analysis of nuclear export factor CRM1 association with its cargo in vivo Mol. Cell. Biol. 25 2005 728 739
8. X. Dong, A. Biswas, K.E. Süel, L.K. Jackson, R. Martinez, H. Gu, and Y.M. Chook Structural basis for leucine-rich nuclear export signal recognition by CRM1 Nature 458 2009 1136 1141
9. J. Etchin, T. Sanda, M.R. Mansour, A. Kentsis, J. Montero, B.T. Le, A.L. Christie, D. McCauley, S.J. Rodig, and M. Kauffman KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia Br. J. Haematol. 161 2013 117 127
10. J. Etchin, Q. Sun, A. Kentsis, A. Farmer, Z.C. Zhang, T. Sanda, M.R. Mansour, C. Barcelo, D. McCauley, and M. Kauffman Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells Leukemia 27 2013 66 74
11. B. Falini, N. Bolli, J. Shan, M.P. Martelli, A. Liso, A. Pucciarini, B. Bigerna, L. Pasqualucci, R. Mannucci, and R. Rosati Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML Blood 107 2006 4514 4523
12. M. Fornerod, M. Ohno, M. Yoshida, and I.W. Mattaj CRM1 is an export receptor for leucine-rich nuclear export signals Cell 90 1997 1051 1060
13. Y. Fu, J.A. Foden, C. Khayter, M.L. Maeder, D. Reyon, J.K. Joung, and J.D. Sander High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells Nat. Biotechnol. 31 2013 822 826
14. M. Fukuda, S. Asano, T. Nakamura, M. Adachi, M. Yoshida, M. Yanagida, and E. Nishida CRM1 is responsible for intracellular transport mediated by the nuclear export signal Nature 390 1997 308 311
15. N. Gould, P.T. Doulias, M. Tenopoulou, K. Raju, and H. Ischiropoulos Regulation of protein function and signaling by reversible cysteine S-nitrosylation J. Biol. Chem. 288 2013 26473 26479
16. T. Güttler, T. Madl, P. Neumann, D. Deichsel, L. Corsini, T. Monecke, R. Ficner, M. Sattler, and D. Görlich NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1 Nat. Struct. Mol. Biol. 17 2010 1367 1376
17. D.T. Hess, A. Matsumoto, S.O. Kim, H.E. Marshall, and J.S. Stamler Protein S-nitrosylation: purview and parameters Nat. Rev. Mol. Cell Biol. 6 2005 150 166
18. P.D. Hsu, D.A. Scott, J.A. Weinstein, F.A. Ran, S. Konermann, V. Agarwala, Y. Li, E.J. Fine, X. Wu, and O. Shalem DNA targeting specificity of RNA-guided Cas9 nucleases Nat. Biotechnol. 31 2013 827 832
19. H. Inoue, M. Kauffman, S. Shacham, Y. Landesman, J. Yang, C.P. Evans, and R.H. Weiss CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth J. Urol. 189 2013 2317 2326
20. M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J.A. Doudna, and E. Charpentier A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity Science 337 2012 816 821
21. O. Kalid, D. Toledo Warshaviak, S. Shechter, W. Sherman, and S. Shacham Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors J. Comput. Aided Mol. Des. 26 2012 1217 1228
22. C. Kasap, O. Elemento, and T.M. Kapoor DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets Nat Chem Biol 2014
23. T.R. Kau, J.C. Way, and P.A. Silver Nuclear transport and cancer: from mechanism to intervention Nat. Rev. Cancer 4 2004 106 117
24. K. Kojima, S.M. Kornblau, V. Ruvolo, A. Dilip, S. Duvvuri, R.E. Davis, M. Zhang, Z. Wang, K.R. Coombes, and N. Zhang Prognostic impact and targeting of CRM1 in acute myeloid leukemia Blood 121 2013 4166 4174
25. N. Kudo, N. Matsumori, H. Taoka, D. Fujiwara, E.P. Schreiner, B. Wolff, M. Yoshida, and S. Horinouchi Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region Proc. Natl. Acad. Sci. USA 96 1999 9112 9117
26. Kuruvilla, J., Gutierrez, M., Shah, B.D., Gabrail, N.Y., de Nully Brown, P., Stone, R.M., Garzon, R., Savona, M., Siegel, D.S., Baz, R., et al. (2013). Preliminary Evidence Of Anti Tumor Activity Of Selinexor (KPT-330) In a Phase I Trial Of a First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) In Patients (pts) With Relapsed / Refractory Non Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). https://ash.confex.com/ash/2013/webprogram/Paper60959.html.
27. R. Lapalombella, Q. Sun, K. Williams, L. Tangeman, S. Jha, Y. Zhong, V. Goettl, E. Mahoney, C. Berglund, and S. Gupta Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia Blood 120 2012 4621 4634
28. M. Lo Conte, and K.S. Carroll The redox biochemistry of protein sulfenylation and sulfinylation J. Biol. Chem. 288 2013 26480 26488
29. Mahaseth, H., Maity, S., Gabrail, N.Y., Mahipal, A., Gericitano, J.F., Shacham, S., Rashal, T., Klebanov, B., Carlson, R., Shacham, E., et al. (2014). Selinexor (KPT-330), an oral, selective inhibitor of nuclear export (SINE) shows anti-prostate cancer (PrCa) activity preclinically & disease control in patients (pts) with chemotherapy refractory, castrate-resistant prostate cancer (CRPC). http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Genitourinary-Tumours-Prostate/Selinexor-KPT-330-an-oral-selective-inhibitor-of-nuclear-export-SINE-shows-anti-prostate-cancer-PrCa-activity-preclinically-disease-control-in-patients-pts-with-chemotherapy-refractory-castrate-resistant-prostate-cancer-CRPC.
30. P. Mali, L. Yang, K.M. Esvelt, J. Aach, M. Guell, J.E. DiCarlo, J.E. Norville, and G.M. Church RNA-guided human genome engineering via Cas9 Science 339 2013 823 826
31. T. Monecke, T. Güttler, P. Neumann, A. Dickmanns, D. Görlich, and R. Ficner Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP Science 324 2009 1087 1091
32. M. Neville, F. Stutz, L. Lee, L.I. Davis, and M. Rosbash The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export Curr. Biol. 7 1997 767 775
33. K.T. Nguyen, M.P. Holloway, and R.A. Altura The CRM1 nuclear export protein in normal development and disease Int. J. Biochem. Mol. Biol. 3 2012 137 151
34. B. Ossareh-Nazari, F. Bachelerie, and C. Dargemont Evidence for a role of CRM1 in signal-mediated nuclear protein export Science 278 1997 141 144
35. V. Pattanayak, S. Lin, J.P. Guilinger, E. Ma, J.A. Doudna, and D.R. Liu High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity Nat. Biotechnol. 31 2013 839 843
36. F.A. Ran, P.D. Hsu, J. Wright, V. Agarwala, D.A. Scott, and F. Zhang Genome engineering using the CRISPR-Cas9 system Nat. Protoc. 8 2013 2281 2308
37. P. Ranganathan, X. Yu, C. Na, R. Santhanam, S. Shacham, M. Kauffman, A. Walker, R. Klisovic, W. Blum, and M. Caligiuri Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia Blood 120 2012 1765 1773
38. A. Shen, Y. Wang, Y. Zhao, L. Zou, L. Sun, and C. Cheng Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis Neurosurgery 65 2009 153 159 discussion 159-160
39. J.E. Smotrys, and M.E. Linder Palmitoylation of intracellular signaling proteins: regulation and function Annu. Rev. Biochem. 73 2004 559 587
40. Y. Smurnyy, M. Cai, H. Wu, E. McWhinnie, J.A. Tallarico, Y. Yang, and Y. Feng DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells Nat. Chem. Biol. 10 2014 623 625
41. K. Stade, C.S. Ford, C. Guthrie, and K. Weis Exportin 1 (Crm1p) is an essential nuclear export factor Cell 90 1997 1041 1050
42. Y.T. Tai, Y. Landesman, C. Acharya, Y. Calle, M.Y. Zhong, M. Cea, D. Tannenbaum, A. Cagnetta, M. Reagan, and A.A. Munshi CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications Leukemia 28 2014 155 165
43. J.G. Turner, J. Dawson, and D.M. Sullivan Nuclear export of proteins and drug resistance in cancer Biochem. Pharmacol. 83 2012 1021 1032
44. P.J. van der Watt, C.P. Maske, D.T. Hendricks, M.I. Parker, L. Denny, D. Govender, M.J. Birrer, and V.D. Leaner The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation Int. J. Cancer 124 2009 1829 1840
45. T. Van Neck, C. Pannecouque, E. Vanstreels, M. Stevens, W. Dehaen, and D. Daelemans Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action Bioorg. Med. Chem. 16 2008 9487 9497
46. C.J. Walker, J.J. Oaks, R. Santhanam, P. Neviani, J.G. Harb, G. Ferenchak, J.J. Ellis, Y. Landesman, A.K. Eisfeld, and N.Y. Gabrail Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias Blood 122 2013 3034 3044
47. P. Wang, G.H. Liu, K. Wu, J. Qu, B. Huang, X. Zhang, X. Zhou, L. Gerace, and C. Chen Repression of classical nuclear export by S-nitrosylation of CRM1 J. Cell Sci. 122 2009 3772 3779
48. D. Xu, A. Farmer, and Y.M. Chook Recognition of nuclear targeting signals by Karyopherin-β proteins Curr. Opin. Struct. Biol. 20 2010 782 790
49. Y. Yao, Y. Dong, F. Lin, H. Zhao, Z. Shen, P. Chen, Y.J. Sun, L.N. Tang, and S.E. Zheng The expression of CRM1 is associated with prognosis in human osteosarcoma Oncol. Rep. 21 2009 229 235
50. Y. Zhang, and Y. Xiong A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation Science 292 2001 1910 1915
51. K. Zhang, M. Wang, A.T. Tamayo, S. Shacham, M. Kauffman, J. Lee, L. Zhang, Z. Ou, C. Li, and L. Sun Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma Exp. Hematol. 41 2013 67 78.e64